Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Clinical Study of GenSci134 in Healthy Male Adults
Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd.
Summary
To check how safe and well-tolerated a single subcutaneous injection of GenSc134 is in healthy male volunteers
Official title: A Randomized, Double-Blind, Placebo and Positive Drug-Controlled, Single-Dose, Dose-Escalation Phase I Clinical Study of GenSci134 Injection in Healthy Adults
Key Details
Gender
All
Age Range
18 Years - 45 Years
Study Type
INTERVENTIONAL
Enrollment
64
Start Date
2025-06-23
Completion Date
2026-04-13
Last Updated
2025-07-08
Healthy Volunteers
Yes
Conditions
Interventions
GenSci134
only one dose of GenSci134 and GenSci134 Placebo to be given, subcutaneous , 7 dose levels will be assigned.
GenSci134 Placebo
only one dose of GenSci134 and GenSci134 Placebo to be given, subcutaneous , 7 dose levels will be assigned.
Recombinant Human Growth Hormone Injection (Norditropin®)
A single dose of 0.2 mg/day, administered once daily (QD) for 28 consecutive days.
Locations (1)
Peking University Third Hospital
Beijing, Beijing Municipality, China